$2.9 B

AXSM Mkt cap, 12-Aug-2020
Axsome Therapeutics Net income (Q2, 2020)-18.3 M
Axsome Therapeutics EBIT (Q2, 2020)-17.8 M
Axsome Therapeutics Cash, 30-Jun-2020190.7 M
Axsome Therapeutics EV2.8 B

Axsome Therapeutics Income Statement

Axsome Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

36.6m34.0m14.0m220.0m

Prepaid Expenses

1.3m1.2m413.1k

Inventories

2.6m

Current Assets

38.0m35.3m15.2m220.4m

PP&E

68.1k51.8k30.6k

Total Assets

38.2m35.6m15.4m220.5m

Accounts Payable

4.1m3.4m3.7m10.9m

Short-term debt

3.3m3.3m2.6m

Current Liabilities

7.2m12.2m10.8m24.5m

Long-term debt

6.7m3.6m17.3m

Total Debt

9.9m6.9m19.9m

Total Liabilities

16.6m18.8m14.4m41.8m

Common Stock

2.5k3.0k3.7k

Additional Paid-in Capital

69.2m93.3m108.5m354.6m

Retained Earnings

(47.6m)(76.6m)(107.6m)(175.9m)

Total Equity

21.6m16.7m937.9k178.7m

Financial Leverage

1.8 x2.1 x16.4 x1.2 x

Axsome Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(27.2m)(28.9m)(31.0m)(68.3m)

Depreciation and Amortization

20.5k42.6k48.9k37.3k

Inventories

(383.9k)

Accounts Payable

2.2m(645.7k)251.8k7.3m

Cash From Operating Activities

(21.3m)(26.5m)(30.1m)(46.4m)

Purchases of PP&E

(9.9k)(32.7k)(16.1k)

Cash From Investing Activities

(104.6k)(9.9k)(32.7k)(16.1k)

Long-term Borrowings

(3.3m)(7.2m)

Cash From Financing Activities

10.0m23.9m10.0m252.4m

Net Change in Cash

(2.6m)(20.1m)206.0m

Interest Paid

772.0k1.3m

Axsome Therapeutics Ratios

USDQ1, 2016

Financial Leverage

1.1 x